<DOC>
	<DOCNO>NCT00002463</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness methotrexate , mechlorethamine , vincristine , procarbazine , prednisone treat child astrocytomas primitive neuroectodermal tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Astrocytomas Primitive Neuroectodermal Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy high-dose methotrexate ( HMTX ) combination mechlorethamine , vincristine , prednisone , procarbazine ( MOPP ) infants young child primitive neuroectodermal tumor ( PNET ) ( include medulloblastoma , anaplastic ependymoma , ependymoblastoma , pineoblastoma ) high-grade astrocytoma . II . Determine whether addition HMTX MOPP ( MMOPP ) improve continuous complete response rate MOPP alone eliminate need salvage radiotherapy patient . III . Determine ability MMOPP provide neuroaxis prophylaxis treat spinal metastasis without radiotherapy infant young child PNET . IV . Determine toxicity regimen term neurologic neuropsychologic sequela , growth , development patient . V. Correlate efficacy regimen histopathologic diagnosis patient . VI . Determine optimum method radiographic evaluation spinal cord disease patient PNET . VII . Determine utility sequential spinal cord radiography mean monitoring PNET patient . OUTLINE : Patients undergo maximum tumor debulking . Patients undergone incomplete resection proceed induction . Patients primary diagnosis primitive neuroectodermal pineal tumor glioblastoma multiforme undergone total resection proceed induction . Induction : Patients receive high dose methotrexate ( HMTX ) IV 6 hour day 1 . Beginning 3 hour completion HMTX infusion , leucovorin calcium ( CF ) administer IV 30 minute every 3 hour 9 dos . Beginning 3 hour completion last CF infusion , oral CF administer every 6 hour 8 dos . Patients receive second HMTX infusion begin 1 week completion first HMTX infusion . Beginning 1 week completion second HMTX infusion , patient receive mechlorethamine IV vincristine IV day 1 8 , oral procarbazine oral prednisone day 1-10 , taper dos prednisone day 11-13 ( MOPP ) . Maintenance : Beginning 4 week initiate first course MOPP , patient receive HMTX day 1 MOPP begin day 4 . Treatment continue every 31 day absence disease progression unacceptable toxicity . After 1 year 14 dos HMTX , whichever occur first , HMTX discontinue treatment MOPP alone continue every 4 week absence disease progression unacceptable toxicity . Treatment discontinue 2 year patient continuous complete remission . PROJECTED ACCRUAL : A total 5-25 patient accrue study within 24-30 month .</detailed_description>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove previously untreated ( except surgically ) primitive neuroectodermal tumor ( include medulloblastoma , anaplastic ependymoma , ependymoblastoma , pineoblastoma ) highgrade astrocytomas Lowgrade astrocytomas optic tract tumor incompletely resect progressive course amenable surgery may also allow Evaluable disease MRI , CT scan , CT myelography PATIENT CHARACTERISTICS : Age : Under 4 year Performance status : Not specify Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count great 1,500/mm3 WBC great 4,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL SGPT le 90 IU/dL Renal : Creatinine clearance great 80 mL/min PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior mechlorethamine , vincristine , procarbazine , prednisone ( MOPP ) No prior highdose methotrexate No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : See Disease Characteristics Other : Recovered acute toxic effect prior therapy Must tyraminefree diet procarbazine administration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebellar astrocytoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
</DOC>